Reply to the letter to the editor ‘Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial’ by Ceccarelli et al.

Annals of Oncology

Volumn 27, Issue 11, 2016, Pages 2138-2139

  Lacouture, M E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCLOMETASONE; DACOMITINIB; DOXYCYCLINE; PROBIOTIC AGENT; QUINAZOLINONE DERIVATIVE;

BIFIDOBACTERIUM; CANCER STAGING; CAUSALITY; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; LETTER; MEDICATION COMPLIANCE; NON SMALL CELL LUNG CANCER; PATIENT COMPLIANCE; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; LUNG TUMOR;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROBIOTICS; QUINAZOLINONES;

EID: 85040694001     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw403     Document Type: Letter

References (2)

1. Ceccarelli G., Schietroma I., Corano Scheri G. et al. Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with Advanced Non-Small-Cell Lung Cancer enrolled in ARCHER-1042 trial. Ann Oncol 2016; 27(11): 2136–2137.
2. Lacouture ME, Keefe DM, Sonis S et al. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Ann Oncol 2016; 27: 1712–1718.